Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing antibiotics aimed at combating bacterial infections. With a particular focus on drug-resistant pathogens, Iterum Therapeutics plc strives to address the critical need for new treatment options in the healthcare sector. The company's flagship product, sulopenem, is an oral and IV antibiotic targeting multi-drug resistant Gram-negative infections, making it a significant player in the fight against antimicrobial resistance. By developing novel treatments for urinary tract and intra-abdominal infections, Iterum plays a pivotal role in both the pharmaceutical and broader healthcare industries. Headquartered in Dublin, Ireland, Iterum Therapeutics plc operates within a market constantly seeking innovative solutions to growing global health challenges, notably the rise in antibiotic resistance. Through its clinical advancements, Iterum not only contributes to patient care but also impacts healthcare policies and practices globally, highlighting its importance in the pharmaceutical landscape.